ImageneBio (IMA) reported a third-quarter 2026 net loss of $15.6 million, compared with a $24.8 million net loss in the prior-year period. Net loss per share, basic and diluted, was $0.91, compared with $2.91 a year earlier.
The company ended September 30 with $126.6 million in cash, cash equivalents and marketable securities and expects its resources to fund planned operations into the first quarter of 2028.
- Research and development expense was $11.3 million, versus $15.2 million in the third quarter of 2025.
- General and administrative expense was $6.0 million, versus $11.0 million a year earlier.
- Topline data from the Phase 2b ADAPTIVE trial in atopic dermatitis is anticipated in the fourth quarter of 2027.
- A Phase 2 study of olevaprubart in alopecia areata is on track to begin by the end of 2026, with initial data expected in 2028.
- No cases of Kaposi sarcoma have been observed across clinical trials to date.
EARLY ACCESS
Receive IKNA Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
